Lurbinectedin Shows Promise in Small Cell Lung Cancer
Small-cell lung cancer (SCLC) accounts for approximately 15% of lung cancer cases and is almost always fatal. The US Food and Drug Administration recently granted Orphan Drug status to lurbinectedin (PM1183), a second-generational investigational inhibitor of RNA polymerase II, an enzyme critical to transcription and DNA repair. The decision was based on preliminary findings from a multicenter, multinational phase 2 trial that included 50 evaluable patients with advanced SCLC. Patients received a 1-hour infusion of lurbinectedin 3.2 mg/m2 every 3 weeks. After a median of 5 cycles, 38% of patients had a partial response and 40% had stable disease. Median progression-free survival was 4.2 months, and mediation duration of response was 5.3 months. The most common adverse event was myelosuppression.
Read more here.
Reference
Perez JMT, Leary A, Besse B, et al. Efficacy and safety of lurbinectedin (PM1183) in small cell lung cancer (SCLC): results from a phase 2 study. Presented at: 2018 American Society of Clinical Oncology; June 1-5, 2018; Chicago, Illinois. Abstract 8570.
